Innate Pharma S.A.
IPH.PA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$167.55M
Close$
$-0.11
108.3% downside
Current Fair Value
108.3% downsideOvervalued by 108.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $167.55 Million |
|---|---|
| Enterprise Value | $171.92 Million |
| Earnings per Share | $-0.55 |
| Beta | 0.88 |
| Outstanding Shares | 93,826,793 |
Return
| Return on Equity | 231.07% |
|---|---|
| Return on Assets | -269.55% |
| Return on Invested Capital | -5416.42% |
Valuation & Multiples
| P/E Ratio | -2.54 |
|---|---|
| PEG | 37.17 |
| Price to Sales | - |
| Price to Book Ratio | -1.28 |
| Enterprise Value to Revenue | 18.29 |
| Enterprise Value to EBIT | -1.7 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | -0.27 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 17, 2026
EPS Estimate
$-0.25
Consensus analyst estimateRevenue Estimate
$5.50 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 25, 2027
EPS Estimate
$-0.25
Consensus analyst estimateRevenue Estimate
$2.54 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Innate Pharma
244 employees
CEO: Mondher Mahjoubi
Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company...